ESSA Pharma Net Worth
ESSA Pharma Net Worth Breakdown | EPIX |
ESSA Pharma Net Worth Analysis
ESSA Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ESSA Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ESSA Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ESSA Pharma's net worth analysis. One common approach is to calculate ESSA Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ESSA Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ESSA Pharma's net worth. This approach calculates the present value of ESSA Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ESSA Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ESSA Pharma's net worth. This involves comparing ESSA Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ESSA Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if ESSA Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ESSA Pharma's net worth research are outlined below:
| ESSA Pharma generated a negative expected return over the last 90 days | |
| ESSA Pharma has high historical volatility and very poor performance | |
| ESSA Pharma may become a speculative penny stock | |
| Net Loss for the year was (26.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ESSA Pharma currently holds about 174.6 M in cash with (19.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ESSA Pharma has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Eikonizo Therapeutics Announces Investment by Novo Nordisk Advancing Lead Candidate EKZ-102 Toward Clinical Development |
ESSA Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ESSA Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ESSA Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 10th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Know ESSA Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ESSA Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ESSA Pharma backward and forwards among themselves. ESSA Pharma's institutional investor refers to the entity that pools money to purchase ESSA Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cibc World Markets Inc. | 2024-09-30 | 73.6 K | D. E. Shaw & Co Lp | 2024-09-30 | 63 K | American Century Companies Inc | 2024-09-30 | 46.7 K | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 44.5 K | Kennedy Capital Management Inc | 2024-09-30 | 41.1 K | Royal Bank Of Canada | 2024-09-30 | 40.8 K | Citadel Advisors Llc | 2024-09-30 | 28.5 K | Group One Trading, Lp | 2024-09-30 | 27.8 K | Geode Capital Management, Llc | 2024-09-30 | 26.9 K | Bvf Inc | 2024-09-30 | 8.7 M | Bellevue Group Ag | 2024-09-30 | 7.9 M |
Follow ESSA Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 75.46 M.Market Cap |
|
Project ESSA Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.96) | (1.86) | |
| Return On Capital Employed | (1.48) | (1.56) | |
| Return On Assets | (1.35) | (1.28) | |
| Return On Equity | (1.48) | (1.41) |
When accessing ESSA Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ESSA Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ESSA Pharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in ESSA Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ESSA Pharma. Check ESSA Pharma's Beneish M Score to see the likelihood of ESSA Pharma's management manipulating its earnings.
Evaluate ESSA Pharma's management efficiency
ESSA Pharma has return on total asset (ROA) of (0.1479) % which means that it has lost $0.1479 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1983) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.86 in 2024. Return On Capital Employed is likely to drop to -1.56 in 2024. At this time, ESSA Pharma's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 383.8 K in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 181.3 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.78 | 1.99 | |
| Net Current Asset Value | 770.50 | 684.89 | |
| Tangible Asset Value | 770.50 | 684.89 | |
| Tangible Book Value Per Share | 1.17 | 1.84 | |
| Enterprise Value Over EBITDA | (33.38) | (31.71) | |
| Price Book Value Ratio | 49.54 | 52.01 | |
| Enterprise Value Multiple | (33.38) | (31.71) | |
| Price Fair Value | 49.54 | 52.01 | |
| Enterprise Value | 63.9 K | 60.7 K |
The operational strategies employed by ESSA Pharma management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Return On Equity (0.20) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ESSA Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ESSA Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ESSA Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ESSA Pharma time-series forecasting models is one of many ESSA Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ESSA Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ESSA Pharma Earnings per Share Projection vs Actual
ESSA Pharma Corporate Management
| Erin Rudsinski | Executive | Profile | |
| CMA CPA | Chief Officer | Profile | |
| Terry Schuenemeyer | Executive | Profile | |
| Neil Thapar | Executive | Profile | |
| Nkengyal Barber | Executive | Profile | |
| Alessandra MD | Chief Officer | Profile |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.